Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis

Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis

Abstract Background Blinatumomab is a BiTE® immuno‐oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL). Aims To assess the efficacy and safety of blinatumomab as first salvage versus second or later salv...

Full description

Bibliographic Details
Main Authors: Max S. Topp, Anthony S. Stein, Nicola Gökbuget, Heinz‐August Horst, Nicolas Boissel, Giovanni Martinelli, Hagop Kantarjian, Monika Brüggemann, Yuqi Chen, Gerhard Zugmaier
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Cancer Medicine
Subjects:
acute lymphoblastic leukemia
BiTE®
blinatumomab
salvage
stem cell transplant
Online Access:https://doi.org/10.1002/cam4.3731

Internet

https://doi.org/10.1002/cam4.3731

Similar Items